Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

NCT05776875 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Low enrollment

Conditions

Hepatocellular Carcinoma
BCLC Stage B Hepatocellular Carcinoma

Interventions

DRUG: Atezolizumab Injection
DRUG: Bevacizumab
COMBINATION_PRODUCT: Transarterial chemoembolization

Sponsor

Yale University

Collaborators

[object Object]